ADORA2A and cancer: Importantly, the blockade of adenosine/A2AR pathway resulted in the enhancement of cancer chemotherapy and immunotherapy in numerous cancer types including lung adenocarcinoma, renal clear cell carcinoma, pheochromocytoma and paraganglioma [43, 81–83].